Edesa Biotech Pushes Forward To Phase 2b Study For Lead Clinical Product [Seeking Alpha]
Edesa Biotech, Inc. - Common Shares (EDSA)
Company Research
Source: Seeking Alpha
Edesa Biotech Pushes Forward To Phase 2b Study For Lead Clinical Product Summary Edesa Biotech received go ahead from FDA to initiate its phase 2b study using EB01 to treat patients with chronic contact dermatitis. There are many other forms of therapies for contact dermatitis such as corticosteroids, antibiotics, and topical creams, but EB01 is being used to treat the root cause of disease. The market opportunity is a large one for contact dermatitis because it is estimated that 13.2 million people in the United States get it. Edesa Biotech came about as the result of a merger with Stellar Biotechnologies and a reverse stock split in June of 2019; its guidance for cash on hand should be more in depth in the upcoming earnings report. EDSA Massive Potential Based On Mechanism Of Action The FDA allowing Edesa to proceed with the phase 2b study using EB01 is very good news. It was all made possible when the FDA sent a "safe to proceed' letter, letting the biotech know the protocol to beg
Show less
Read more
Impact Snapshot
Event Time:
EDSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDSA alerts
High impacting Edesa Biotech, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
EDSA
News
- Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech to Participate in Bloom Burton Healthcare Investor ConferenceAccesswire
- Edesa Biotech to Participate in Upcoming Investor ConferencesAccesswire
- Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory ConferenceAccesswire
- Edesa Biotech to Participate in Barclays Global Healthcare ConferenceAccesswire
EDSA
Analyst Actions
- 2/14/24 - HC Wainwright
EDSA
Sec Filings
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- EDSA's page on the SEC website